Factors associated with mortality after breast cancer metastasis

被引:88
作者
Jung, Su Yon [1 ]
Rosenzweig, Margaret [2 ,3 ]
Sereika, Susan M. [1 ,3 ,4 ]
Linkov, Faina [5 ]
Brufsky, Adam [2 ]
Weissfeld, Joel L. [1 ,2 ]
机构
[1] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15261 USA
[3] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA
[5] Univ Pittsburgh, Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15261 USA
关键词
Advanced breast cancer; Prognostic factors; Comorbidity; LONG-TERM SURVIVAL; BODY-MASS INDEX; PROGNOSTIC-FACTORS; 1ST RECURRENCE; WOMEN; COMORBIDITY; PREMENOPAUSAL; HYPERTENSION; THERAPY; RELAPSE;
D O I
10.1007/s10552-011-9859-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is generally accepted that patients with breast cancer metastases have very poor survival. Metastatic breast cancer patients can be considered a heterogeneous population with a varied clinical course, which underscores the need for accurate prediction of survival based on prognostic factors. The purpose of the present study was to identify factors related to survival in breast cancer patients after diagnosis with metastatic disease. A total of 557 patients with breast cancer metastasis diagnosis seen at one large urban practice have been followed up between 1 January, 1999 and 30 June, 2010. Demographic, tumor characteristics, clinical factors as predictors of survival were analyzed using log-rank test and Cox regression model. The median survival length was 39 months (range 1-138 months) with 154 (27.7%) alive and 403 (72.3%) dead at the end of follow-up period. This study demonstrated that a history of hypertension, ER/PR status, HER2 status, metastasis-free interval, metastatic location (including brain, bone and liver), and BMI at diagnosis with metastatic breast cancer were the most relevant prognostic factors for survival after metastatic disease diagnosis. Findings of this study may form a foundation for the growing corpus of knowledge explaining the outcome differences in treatment of patients with metastatic breast cancer, potentially helping to create tailored counseling and personalized treatment approaches for this vulnerable group.
引用
收藏
页码:103 / 112
页数:10
相关论文
共 50 条
[21]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[22]   FACTORS PREDICTING FOR RESPONSE, TIME TO TREATMENT FAILURE, AND SURVIVAL IN WOMEN WITH METASTATIC BREAST-CANCER TREATED WITH DAVTH - A PROSPECTIVE EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY [J].
FALKSON, G ;
GELMAN, R ;
FALKSON, CI ;
GLICK, J ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (12) :2153-2161
[23]   RELAPSE OF BREAST-CANCER AFTER ADJUVANT TREATMENT IN PREMENOPAUSAL AND PERIMENOPAUSAL WOMEN - PATTERNS AND PROGNOSES [J].
GOLDHIRSCH, A ;
GELBER, RD ;
CASTIGLIONE, M .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (01) :89-97
[24]   Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer [J].
Gordon, N. H. ;
Silverman, P. ;
Lasheen, W. ;
Meinert, J. ;
Siminoff, L. A. .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 102 (03) :301-312
[25]  
Grasic-Kuhar C, 2008, NEOPLASMA, V55, P416
[26]  
Grau AM, 2005, AM SURGEON, V71, P164
[27]   Cancer and hypertension - An unresolved issue [J].
Hamet, P .
HYPERTENSION, 1996, 28 (03) :321-324
[28]  
HENDERSON IC, 1989, CANCER PRINCIPLES PR, P1197
[29]   MULTIVARIATE-ANALYSIS OF PROGNOSTIC FACTORS IN METASTATIC BREAST-CANCER [J].
HORTOBAGYI, GN ;
SMITH, TL ;
LEGHA, SS ;
SWENERTON, KD ;
GEHAN, EA ;
YAP, HY ;
BUZDAR, AU ;
BLUMENSCHEIN, GR .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (12) :776-786
[30]  
HORTOBAGYI GN, 2004, ASCO ANN M P JUL 1 S, V22, P585